10/30!2020
`
`Outcomes of Kahook Dual Blade Goniotomy with and without Phacoemulsification Cataract Extraction - 5cienceDirect
`
`ScienceDirect
`
`Access through your institution
`
`'= Outline
`
`Get Access Share Export
`
`Ophthalmology Glaucoma
`Volume 1, Issue 1,July—August 2018, Pages 75-81
`
`Original Article
`Outco mes of Kahook Dual Blade Gonioto my with and without
`Phacoe mulsification Cataract Extraction
`
`Presented at: the American Glaucoma Society Annual Meeting, New York, NY, March 2018.
`
`Erin G. Sieck MD 1, Rebecca S. Epstein MD 1, Jeffrey B. Kennedy MD 1, Jeffrey R. SooHoo MD 1, Mina B. Pantcheva MD
`
`1, Jennifer L. Patnaik PhD 1, Brandie D. Wagner PhD 1' �, Anne M. Lynch MD 1, Malik Y. Kahook MD 1, Leonard K.
`
`Seibold MD 1
`
`Show more �r
`
`https:��doi.org�10.1016�j.ogla.�018.06.006
`
`
`
`Get rights and content
`
`Purpose
`
`To determine the effectiveness and safety of Kahook Dual Blade (KDB) gonioto my in reducing
`
`intraocular pressure (IOP) and medication need in glaucoma patients when comhined with
`
`phacoe mulsification or as a standalone procedure.
`
`Design
`
`Retrospective study.
`
`Participants
`
`A total of 197 eyes fro m 143 patients were reviewed.
`
`Methods
`
`https://www.scienced irect.com/science/article/abs/pi i/S2589419618300413
`
`Patent Owner Ex. 2002-0001
`
` 1 /3
`
`

`

`10!30!2020
`
`
`
`Outcomes of Kahook Dual Blade Goniotomy with and without Phacoemulsification Cataract Extraction - 5cienceDirect
`
`Thirty-two eyes underwent KDB goniotomy alone and 165 eyes underwent KDB goniotomy
`combined with phacoemulsification cataract surgery (phaco-KDB).
`
`Main Outco me Measures
`
`Surgical success, defined as IOP reduction of at least 20% from baseline at 12 months, and/or
`reduction of at least 1 glaucoma medication.
`
`Results
`
`At 12 months, the success rate was 71.8% for the phaco-KDB group and 68.8% for the KDB-alone
`group. In the phaco-KDB group at 12 months (n =124}, mean IOP was significantly reduced from
`16.7 {standard error [SE] 0.4) mmHg on 1.9 (SE 0.1) medications to 13.8 (SE 0.4) mmHg on 1.5 (SE
`0.1) medications. In the KDB-alone group at 12 months (n =1G), me an IOP was significantly
`reduced from 20.4 {SE 1.3) mmHg on 3.1 {SE 0.2} medications to 14.1 {SE 0.9} mmHg on 2.3 (SE
`0.4) medications. The most common complications were transient hyphema (17.3% at day 1} and
`IOP spike >10 mmHg from baseline at 1 week {10.2%). LogMAR visual acuity at 12 months was
`unch anged from baseline in the KDB -alone group (0.2].8 [SE 0.07] and 0.306 [5E 0.09], respectively,
`P = 0.244) and significantly improved in the phaco -KDB group {0.184 [SE 0.02] and 0.340 [SE 0.03],
`P < o.00l).
`
`Conclusions
`
`Goniotomy with the KDB has a favorable safety profile and is an effective procedure at reducing
`IOP and medication burden as a standalone procedure or combined with phacoemulsification.
`
`Previous
`
` Next
`
`AbUreviations and Acrony ms
`
`EVP, episclexal venous pxessuxe; IOP, intxaoculax pxessure ; KDB, Kahook Dual Blade ;
`
`POAG, pri mary open-angle glauco ma; SE, standard error; TM, traUecular meshwork
`
`Recom mended articles
`
`Citing articles (0)
`
`Financial Disclosure(s): The authors) have made the following disclosure(s): E.G.S.: Consultant New World Medical.
`
`M.Y.K.: Patent Kahook Dual Blade, which is licensed by New World Medical. The University of Colorado receives
`royalties for the Kahook Dual Blade.
`
`https://www.sciencedirect.comiscience/article/abslpiilS2589419618300413
`
`Patent Owner Ex. 2DD2-0002
`
`
`
` 2/3
`
`

`

`10/30/2020
`
`Outcomes of Kahook Dual Blade Goniotomy with and without Phacoemulsification Cataract Extraction - 5cienceDirect
`
`HUMAN SUBJECTS: Human subjects were included in this study. The Colorado Multiple Institutional Review Board
`approved this study. The study conformed to the tenets of the Declaration of Helsinki. Patients did not provide
`
`consent as this was a retrospective chart review.
`
`No animal subjects were used in this study.
`
`Author Contributions:
`
`Conception and design: Sieck, Epstein, Kennedy, Patnaik, Wagner, Lynch, Kahook, Seibold
`
`Data collection: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Seibold
`
`Analysis and interpretation: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Patnaik, Wagner, Lynch, Kahook, Seibold
`
`Obtained funding: N�A
`
`Overall responsibility: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Patnaik, Wagner, Lynch, Kahook, Seibold
`
`View full text
`
`© 2018 by the American Academy of Ophthalmology
`
`? �'�• � About ScienceDirect
`
`� �
`, �""� �. Remote access
`ELSEVIER
`
`Shopping cart
`
`Advertise
`
`Contact and support
`
`Terms and conditions
`
`Privacy policy
`
`We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
`Copyright ©2020 Elsevier B.V. or its licensors or contributors. 5cienceDirect ®is a registered trademark of Elsevier B.V.
`ScienceDirect o is a registered trademark of Elsevier B.V.
`
`C�.RELXTM
`
`https:l/www.sciencedirect.com/science/article/abs/pii/S2589419618300413
`
`Patent Owner Ex. 2002-0003
`
`
`
`3/3
`
`